Moreover, 11a displayed synergistic antiproliferativeactivity when tested in MOLM-13 cells in combination with the AMLapproved drug venetoclax, known BCL-2 inhibitor, while weak or nosynergy was observed in combination with other AML drugs such as gliterinib,cytarabine, and sorafenib.146. This evidence concerns the gene BCL2 and acute myeloid leukemia.